Objective To evaluate ongoing adherence to disease modifying therapies (DMT) among individuals with multiple sclerosis and test the utility of the Health Beliefs Model (HBM) to predict adherence.
Design Telephone survey completed at baseline with monthly telephone follow-up for 6 months.
Setting Veterans Health Administration.
Participants Eighty-nine veterans with MS actively enrolled in a regional VA MS outpatient clinic currently prescribed DMT.
Measures Demographic information. Selected items from the Adherence Determinants Questionnaire (ADQ) and Barriers to Care Scale (BACS).
Results Adherence in this population of ongoing DMT users was relatively high (over 80% achieved 80% adherence at follow-up time points). Logistic regression and hierarchical multiple regression analyses controlling for demographics and disease duration were employed to examine the relationship of HBM constructs of perceived susceptibility, severity, benefits, and barriers to DMT adherence and satisfaction at 2-, 4- and 6-month follow-up. Of the four HBM constructs, only perceived benefits uniquely predicted both outcomes across multiple time points.
Conclusion Sustained adherence to DMT remains a challenge for an important minority of individuals with MS. The Health Beliefs Model provides insight into psychosocial mechanisms that maintain adherence behavior. In particular, focus upon the perceived benefits of ongoing DMT therapy may be a promising focus for future interventions. Multiple Sclerosis 2007; 13: 1146—1152. http://msj.sagepub.com
Burks JSA practical approach to immunomodulatory therapy for multiple sclerosis. Phys Med Rehabil Clin N Am2005; 16: 449—66.
2.
Mohr DC, Goodkin DE, Masuoka L., Dick LP, Russo D., Eckhardt J. et al. Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis. Multiple Sclerosis1999; 5: 192—97.
3.
Hadjimichael O., Volmer TLAdherence to injection therapy in multiple sclerosis: Patients survey. Neurology1999 ; 53: 1190—97.
4.
Becker MH, Maiman LASociobehavioral determinants of compliance with health and medical care recommendations . Med Care1975; 13: 10—24.
5.
Aiken LS, West SG, Woodward CK, Reno RRHealth beliefs and compliance with mammography-screening recommendations in asymptomatic women. Health Psychol1994; 13: 122—29.
6.
Arneson SW, Triplett JL, Hahnemann B., Merington E.Factors affecting parental use of child automobile safety restraints. Child Health Care1985; 13: 181—86.
7.
Cerkoney KA, Hart LKThe relationship between the Health Belief Model and compliance of persons with diabetes mellitus. Diabetes Care1980 ; 3: 594—98.
8.
Simonds JF, Goldstein D., Kilo C., Hoette S.The role of health beliefs in the regimen adherence and metabolic control of adolescents and adults with diabetes mellitus. J Consult Clin Psychol1987; 55: 139—44.
9.
Hershey JC, Morton BG, Davis JR, Reichgott MJPatient compliance with antihypertensive medication. Am J Public Health1980; 70: 1081—89.
10.
Vollmer TL, Hadjimichael O., Preiningerova J., Ni W., Buenconsejo J.Disability and treatment patterns of multiple sclerosis patients in United States: A comparison of veterans and nonveterans. J Rehabil Res Dev2002; 39: 163—74.
11.
Beatty WW, Paul RH, Wilbanks SL, Hames KA, Blanco CRIdentifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment. Neurology1995; 45: 718—23.
12.
DiMatteo MR, Hays RD, Gritz ER, Roshan B.Patient adherence to cancer control regimens: Scale development and initial validation. Psychol Assess1993; 5: 102—12.
13.
Schwartz C., Vollmer TL, Lee H.Reliability and validity of two self-report measures of impairment and disability for MS. Neurology1999; 52: 63—70.
14.
Heckman TG, Somlai AM, Peters J., Walker J., Otto-Salaj L., Galdabini CA et al. Barriers to care among persons living with HIV/AIDS in urban and rural areas. AIDS Care1998; 10: 365—75.
15.
Stone VEStrategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin Infect Dis2001; 33: 865—72.
16.
Haynes RB, McKibbon KA, Kanani R.Systematic review of randomized trials of interventions to assist patients to follow prescriptions for medications. Lancet1997; 348: 383—86.
17.
Rogers PG, Bullman WRPrescription medicine compliance: A review of the baseline of knowledge. A report of the National Council on Patient Information and Education. Journal of Pharmacoepidemiology1995; 2: 3.
18.
Roter DL, Hall JA, Merisca R., Nordstrom B., Cretin D., Svarstad B.Effectiveness of interventions to improve patient compliance: A meta-analysis . Med Care1998; 36: 1138—61.
19.
Osterberg L. , Blaschke T.Adherence to medication. N Engl J Med2005; 353: 487—97.
Mohr DC, Boudewyn AC, Likosky W., Levine E., Goodkin DEInjectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med2001; 23: 125—32.
22.
Fraser C., Hadjimichael O., Volmer TLPredictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis. J Neurosci Nurs2003; 35: 163—74.
23.
Harrison JA , Mullen PD, Green LWA meta-analysis of studies of the health belief model with adults. Health Educ Res1992; 7: 107—16.
24.
Tremlett HL , Oger JOInterrupted therapy: Stopping and switching of the beta-interferons prescribed for MS. Neurology2003; 61: 551—54.
